Intra-Cellular price target raised to $82 from $72 at Needham

Needham analyst Ami Fadia raised the firm’s price target on Intra-Cellular to $82 from $72 and keeps a Buy rating on the shares. The company announced a slight delay in the readout of the first of three major depressive disorder, MDD, studies from Q1 to April, though the firm retains its expectations for continued growth of Caplyta, upcoming data readouts in MDD, and progress of its pipeline in the medium/long term, the analyst tells investors in a research note.